Evolution Wealth Advisors’s Standard BioTools LAB Stock Holding History

Evolution Wealth Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Hold	12,210	–	–	﹤0.01%	181
2026 Q1	$11.2K	Hold	12,210	–	–	﹤0.01%	176
2025 Q4	$15.6K	Hold	12,210	–	–	﹤0.01%	165
2025 Q3	$15.9K	Hold	12,210	–	–	﹤0.01%	165
2025 Q2	$14.7K	Hold	12,210	–	–	﹤0.01%	170
2025 Q1	$13.2K	Hold	12,210	–	–	﹤0.01%	149
2024 Q4	$21.4K	Hold	12,210	–	–	﹤0.01%	143
2024 Q3	$23.6K	Hold	12,210	–	–	﹤0.01%	134
2024 Q2	$21.6K	Hold	12,210	–	–	﹤0.01%	133
2024 Q1	$33.1K	Buy	+12,210	New	+$29.5K	0.01%	131

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Evolution Wealth Advisors's LAB Position: Q2 2026 in Review

Evolution Wealth Advisors held its Standard BioTools (LAB) position steady in Q2 2026 at 12,210 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #181.

Evolution Wealth Advisors first reported a position in LAB in Q1 2024 and has held it in 10 quarters since. The position peaked at $33.1K in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Evolution Wealth Advisors held 12,210 shares of Standard BioTools worth $10K as of Q2 2026.
Evolution Wealth Advisors left its Standard BioTools share count unchanged in Q2 2026.
Standard BioTools made up ﹤0.01% of Evolution Wealth Advisors's portfolio in Q2 2026, its #181 holding.
Evolution Wealth Advisors first reported a position in Standard BioTools in Q1 2024 and has held it in 10 quarters since.
Evolution Wealth Advisors's Standard BioTools position peaked at $33.1K in Q1 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Evolution Wealth Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.